Skip to content
PaperFren

Oncology outcomes

Can CHK1 blockade help BRCA-wild-type resistant ovarian cancer?

Giudice E, Huang TT, Nair JR, et al. · Nature communications · 2024

Open access · cc by · source: Europe PMC

In 49 heavily pretreated BRCAwt platinum-resistant HGSOC patients, prexasertib yielded ~29–33% ORR with manageable but frequent neutropenia before early trial stop.

Save to libraryView originalAsk PaperFrenStudy view

Study at a glance

Design
Other — Open-label single-arm phase 2 basket cohorts (NCT02203513 cohorts 5–6) of IV prexasertib in BRCAwt platinum-resistant HGSOC; early sponsorship stop
N
N=49 · 24 biopsiable (cohort 5) + 25 non-biopsiable (cohort 6); 39 RECIST-evaluable
Population
Adults with BRCA wild-type platinum-resistant recurrent high-grade serous ovarian/related carcinoma
Outcome
ORR (primary), safety, PFS; exploratory replication-stress biomarkers

Structured fields used in claim comparison tables when every cited study has a complete layer.

Key findings

Among 39 evaluable patients, ORR was 33.3% (cohort 5) and 28.6% (cohort 6); median PFS 4 vs 6 months; neutropenia in 85.7%. High POLA1/POLE/GINS3 transcripts tracked with PFS <6 months.

Methodology

An NCI open-label phase 2 enrolled cohorts with or without biopsiable disease, giving IV prexasertib 105 mg/m² every 2 weeks, assessing RECIST ORR, PFS, safety, and exploratory biopsy/blood biomarkers.

Limitations

Not a randomized comparative efficacy trial; early stop limited definitive primary-endpoint evaluation and generalizability.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.

Related papers in this topic

Same topic cluster — not a recommendation engine.